Mercado global de quimioembolização transarterial (TACE) – Tendências do setor e previsão para 2031

Análise e dimensão do mercado de quimioembolização transarterial (TACE)

No mercado da quimioembolização transarterial (TACE), a terapêutica neoadjuvante refere-se à utilização de TACE como tratamento pré-cirúrgico para o cancro do fígado. Ao administrar TACE antes da cirurgia, os médicos pretendem reduzir o tumor e melhorar a viabilidade e a taxa de sucesso de procedimentos cirúrgicos subsequentes, como a ressecção ou o transplante hepático. O TACE neoadjuvante pode ajudar a reduzir o tamanho do tumor, controlar o crescimento do tumor e potencialmente aumentar a probabilidade de remoção completa do tumor durante a cirurgia. Esta abordagem sublinha o papel do TACE como uma ferramenta valiosa no tratamento abrangente do cancro do fígado, oferecendo aos doentes uma oportunidade de melhores resultados cirúrgicos e prognóstico global.

O tamanho global do mercado de quimioembolização transarterial (TACE) foi avaliado em 2,29 mil milhões de dólares em 2023 e deverá atingir os 4,32 mil milhões de dólares até 2031, com um CAGR de 8,25% durante o período de previsão de 2024 a 2031. Além dos insights sobre cenários de mercado como o valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análises especializadas aprofundadas, epidemiologia de pacientes, análise de pipeline , análise de preços e enquadramento regulamentar.

Âmbito do relatório e segmentação de mercado       

Definição de mercado

O procedimento de quimioembolização transarterial (TACE) é utilizado para tratar o cancro do fígado. Envolve a injeção de medicamentos quimioterápicos diretamente nos vasos sanguíneos que irrigam o tumor, seguida da inserção de pequenas partículas para bloquear esses vasos, cortando assim o fornecimento de sangue ao tumor e administrando altas doses de quimioterapia diretamente às células cancerígenas. O TACE visa reduzir os tumores, aliviar os sintomas e potencialmente melhorar os resultados dos doentes.

Dinâmica de mercado da quimioembolização transarterial (TACE)

Motoristas                                                                                          

• Elevada exigência de quimioembolização transarterial (TACE) devido à natureza minimamente invasiva

Os doentes e os profissionais de saúde são atraídos pelo TACE devido à sua abordagem menos invasiva em comparação com a cirurgia tradicional, levando a tempos de recuperação e internamentos hospitalares reduzidos. Este apelo traduz-se numa maior aceitação e satisfação dos doentes, impulsionando a procura de procedimentos TACE. Além disso, o risco reduzido de complicações associadas às técnicas minimamente invasivas melhora o perfil de segurança da TACE, tornando-a uma opção atrativa para uma população mais vasta de doentes. Como resultado, a crescente preferência por tratamentos minimamente invasivos impulsiona a expansão do mercado TACE, oferecendo aos doentes opções terapêuticas eficazes com menos riscos processuais e melhoria da qualidade de vida.

• Avanços tecnológicos rápidos aumentam a precisão dos procedimentos

Innovations in imaging techniques, such as cone-beam CT and MRI, allow for better visualization of tumors and surrounding vasculature, aiding in precise catheter placement and drug delivery. Moreover, advancements in catheter technology enable more accurate and controlled embolization of tumor-feeding vessels, reducing complications and improving outcomes. The development of novel embolic agents with improved characteristics, such as increased biocompatibility and prolonged drug release, further enhances the therapeutic efficacy of TACE. These technological advancements attract both patients and healthcare providers, fostering greater adoption of TACE and driving market growth.

Opportunities

• Growing Screening Programs Increases the Demand of Transarterial Chemoembolization (TACE)

Screening programs increase early detection rates, identifying liver tumors at earlier, more treatable stages. As a result, more patients become eligible candidates for TACE, boosting its demand and adoption. Early detection through screening programs also improves overall patient outcomes and survival rates. Moreover, increased awareness of liver cancer risk factors prompts more individuals to undergo screenings, expanding the pool of potential TACE recipients. Overall, the growth of screening initiatives enhances the market for TACE by identifying more patients who can benefit from this minimally invasive treatment option.

• High Demand for Transarterial Chemoembolization (TACE) due to Favorable Reimbursement Policies

When insurance providers or government healthcare systems offer reimbursement for TACE procedures, it encourages more patients to opt for this treatment, expanding the market demand. Moreover, healthcare facilities are more inclined to offer TACE services when they are adequately reimbursed, leading to increased accessibility and availability of the procedure. Favorable reimbursement also incentivizes healthcare providers to invest in advanced equipment and training, further enhancing the quality and uptake of TACE treatments. Overall, robust reimbursement policies play a pivotal role in fostering the widespread adoption of TACE and driving market growth in liver cancer treatment.

Restraints/Challenges

• High Risk of Complications Limits the Adoption of Transarterial Chemoembolization (TACE)

While TACE is generally considered safe, potential complications such as liver damage, post-embolization syndrome, and infection can occur, impacting patient outcomes and confidence in the procedure. These risks may lead to hesitation among both patients and healthcare providers in opting for TACE as a treatment option for liver cancer. Concerns about adverse events may also contribute to longer decision-making processes or alternative treatment choices, ultimately affecting the demand for TACE procedures and restraining market growth.

• Cost Considerations Hampers the Demand of Transarterial Chemoembolization (TACE)

Despite reimbursement policies, the expenses associated with TACE procedures, including the cost of chemotherapy drugs, imaging studies, hospitalization, and follow-up care, can be substantial. For patients, particularly those without adequate insurance coverage or in regions with high out-of-pocket expenses, the financial burden may deter them from pursuing TACE treatment. These cost constraints limit the adoption of TACE, particularly in healthcare systems with constrained budgets or limited resources, ultimately impacting market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2023, Bristol-Myers Squibb initiated the CheckMate 74W trial, evaluating Nivolumab with Ipilimumab and Nivolumab alone in combination with Trans-Arterial ChemoEmbolization (TACE) for participants with intermediate stage liver cancer. Nivolumab and Ipilimumab are immunotherapy drugs that work by enhancing the body's immune response against cancer cells, while TACE is a localized treatment that combines chemotherapy and embolization to target liver tumors directly. This trial aims to assess the efficacy and safety of these treatment combinations, potentially offering new therapeutic options for individuals with this type of cancer

Transarterial Chemoembolization (TACE) Market Scope

The market is segmented on the basis of procedure type, product type, indication and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Procedure Type

• Conventional TACE
• DEB-TACE

Product Type

• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Indication

• Unresectable HCC
• Early-Stage HCC

End-User

• Hospitals and Clinics
• Cancer Research Centers

Transarterial Chemoembolization (TACE) Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, procedure type, product type, indication and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the market, driven by rising awareness of hepatocellular carcinoma (HCC) and advancements in early diagnosis techniques. The region benefits from substantial research and development investments, further fueling market expansion. These factors collectively contribute to North America's prominence in TACE, reflecting a robust ecosystem for addressing liver cancer and fostering innovation in treatment modalities.

Asia-Pacific is expected to experience significant growth, driven by rising incidences of hepatocellular carcinoma (HCC) in the region. In Japan, hepatitis C continues to be a primary factor contributing to HCC cases, whereas in much of Asia, hepatitis B virus is the predominant cause. This distinction underscores regional variations in the etiology of liver cancer, shaping the demand for treatments and highlighting the importance of tailored healthcare strategies across different parts of Asia.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

O mercado também fornece análises de mercado detalhadas para o crescimento de cada país em despesas de saúde para equipamentos de capital, base instalada de diferentes tipos de produtos para o mercado, impacto da tecnologia utilizando curvas de linha de vida e mudanças nos cenários regulamentares de saúde e o seu impacto no mercado. Os dados estão disponíveis para o período histórico 2016-2021.

Análise de mercado do cenário competitivo e quimioembolização transarterial (TACE)

O cenário competitivo do mercado fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.

Alguns dos principais players que operam no mercado são:

• Questex (EUA)
• Siemens Healthcare GmbH (Alemanha)
• Intermountain Healthcare (EUA)
• Autoridade Provincial dos Serviços de Saúde (Canadá)
• Instituto de Investigação do Cancro (EUA)
• (EUA)
• Corporação Científica de Boston (EUA)
• Hikma Pharmaceuticals PLC (Jordânia)
• Isofol Medical AB (publ) (Suécia)
• (Japão)
• Novartis AG (Suíça)
• (EUA)
• Sirtex SIR-Spheres Pty Ltd. (Austrália)
• Spectrum Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd (Suíça)
• Bayer AG (Alemanha)
• Hepion Farmacêutica (EUA)
• Polaris Farmacêutica (EUA)
• Chugai Pharmaceutical Co., Ltd. (Japão)
• Merck & Co., Inc.

SKU-58999